Septerna (SEPN) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Septerna (SEPN) has outperformed Zenas BioPharma (ZBIO) over the past year, gaining 64.1% versus a gain of 1.3%. Septerna is the larger company by market cap ($1.78 billion vs $1.77 billion), about 1.0 times the size. Septerna converts more of its revenue into profit, with a net margin of -106.4% versus -3777.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SEPN | ZBIO |
|---|---|---|
| Share price | $38.23 | $27.15 |
| Market cap | $1.78B | $1.77B |
| 1-day change | +3.60% | +3.47% |
| YTD return | +32.35% | -27.73% |
| 1-year return | +64.07% | +1.31% |
| EPS (TTM) | $-0.54 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $45.95M | $10.00M |
| Revenue growth (YoY) | +4174.51% | +100.00% |
| Net income (latest FY) | $-48.88M | $-377.74M |
| Operating margin | -148.63% | -3830.57% |
| Net margin | -106.37% | -3777.37% |
| 52-week high | $51.10 | $44.60 |
| 52-week low | $17.55 | $13.50 |
| Distance from 52-week high | -25.19% | -39.13% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +41.83% | +76.35% |
| Average volume | 390.47K | 733.34K |
| Shares outstanding | 46.68M | 65.18M |
| Employees | 123 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEPN has outperformed ZBIO by 62.8 percentage points over the past year.
- Septerna is more profitable, keeping -106.4 cents of every revenue dollar as net income versus -3777.4 cents for Zenas BioPharma.
- Septerna grew revenue faster in its latest fiscal year (+4174.51% vs +100.00%).
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
SEPN vs ZBIO FAQ
Which is bigger, Septerna or Zenas BioPharma?
Septerna (SEPN) is larger, with a market capitalization of $1.78B compared with $1.77B for Zenas BioPharma (ZBIO).
Which stock has performed better over the past year, SEPN or ZBIO?
SEPN returned +64.07% over the past 12 months, compared with +1.31% for ZBIO (price return, excluding dividends). Past performance does not predict future results.
Are Septerna and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.